Looking for the best cell phone service provider? Consumer Reports has honest ratings and reviews on cell phone service providers from the unbiased experts you can trust.

Physicians who treat sickle cell disease face some of the most complex and resource-intensive care in medicine, and a national survey now shows they experience markedly higher burnout, raising ...

There are many serious health conditions and diseases that affect the lungs and are associated with aging, like pneumonia, lung cancer, and chronic obstructive pulmonary disease. Researchers have now ...

Hematology-oncology-trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in ...

(WASHINGTON — Mar. 12, 2026) — Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care ...

It’s taken 3½ years, but mortgage rates finally have a “five-handle.” Borrowing costs for home loans pushed above 6% in September 2022 and have been at least that high – and occasionally in the 7% ...

Homebuyers are welcoming something they haven't seen since 2022: mortgage rates below 6%. The reduction could offer home hunters some financial breathing room as the spring home-buying season gets ...

The evidence is patchy on whether lower rates have meaningfully spurred more activity, as the Trump administration floats measures it says will make housing more affordable. Source: Freddie Mac. By ...

Mesoblast Limited (NASDAQ: MESO) shares are down during Thursday’s premarket session after the company provided data presented at the Tandem Meetings of the American Society for Transplantation and ...

If the average on the 30-year fixed mortgage moved to 6%, 5.5 million current homeowners would be able to benefit from a refinance. About 20% of borrowers have mortgages with a rate over 6%. A ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...